Pipeline boom, profit misses guidance floor

Filed result: PAT ₹30.4 Cr, grew 43.8% YoY

Revenue ₹180.2 Cr, actual YoY growth 30.6%

Transcript notes actual growth is 42%, initially misspoke as 36%

OPM 29.8%, implies EBITDA ~54 Cr (30% of 180)

Management stated 30M units, 18 products mapped, commercial revenue flowing

Scaled down ₹100 Cr greenfield sterile plan; redirecting capex to expand oral capacity at Apnar and US. Now pilot-only approach for injectables.

Acquired opportunistically not planned; now at 80-90% utilization (30M units Q1), 3rd and 4th production lines underway vs initially unplanned capex.

Shifted from volume (INR8→40 Cr YoY, 5x jump) to profitability; Q1 revenue -2% QoQ but margin focus 35-40%. Targeting INR50-60 Cr with 35-40% EBITDA.

Revenue 30-40%, PAT 50-60%, EBITDA margin 29-31% unchanged. Q1 PAT at 43.8% requires acceleration in Q2-Q4 to meet 50-60% target.

H1 is seasonally weak; last year Q1 was low single-digit %. Full year guidance 18-20% on track. Multiple new product registrations coming into effect this year will support margins.

Grew 5x YoY (INR8→40 Cr). Q1 focus shifted to profitability over volume; targeting INR50-60 Cr revenue with 35-40% EBITDA. Expect 30-40% YoY growth going forward.

Mix of acquisitions and organic development; strategy continues. Gross margin on sequential basis affected by product mix (regulated vs emerging). H1 weaker; expect improvement H2.

H1 vs H2 seasonality in business. Q4 had ₹17 Cr other income; this quarter ~₹0. Even sequentially, grew for first time ever. Gross margin improved 1% QoQ.

4-point go-to-market: Zoraya (own label), Amerisyn (government), B2B (out-license), CDMO/CMO. All 35 ANDAs have commercial partners mapped. Nothing sits unapproved without a strategy.

Launches this quarter were immaterial to top-line; more planned next quarter and Q4. Sticking to FY27 guidance; if revisions needed in couple quarters, will discuss.

Scaled down to prioritize oral solid capacity expansion at Apnar/US. Sterile moving to H2 this year as pilot. Change in object pending shareholder approval; decision based on better ROI.

6 products commercialized from Apnar. 30M units produced Q1. 18 products mapped (launches + transfers from US). Expect 3-4 years to reach ₹2,500-3,000 Cr with similar/better margins.

80-90% utilization (much of this product qualification, not revenue). Capex FY27: ₹100-120 Cr across subs; major items are oral capacity and injectable pilot. Next year: ₹60-75 Cr minimum run-rate.

Too premature to map revenue. Planning to file 100-120 products in EU over next year. Strong pipeline but revenue number not predictable yet.

Opportunities mapped and ongoing but too premature to comment. Excluded from 3-4 year guidance because approval paths unpredictable. Will be incremental upside if achieved.

Waiting for India-US trade agreement details. Already have US facility, so margin neutral. 2-year timeline too long to worry about; tariff scenarios change historically.

Guided in prior calls; reaffirmed this call. Q1 at 30.6% suggests acceleration needed or lower end likely.

Quantified target with roadmap: 58 ANDAs (23 live, 35 planned), 900+ emerging market registrations in pipeline, CDMO/CMO growth, branded generics ₹50-60 Cr.

Q1 at 30% on track. Guided maintained despite emerging market H1 weakness; Q2-Q4 should recover.

Implies margin expansion while scaling 13x revenue base; dependent on high-margin ANDA mix and CDMO leverage.

Oral solid capacity expansion (Apnar 3rd/4th lines, US), injectable pilot startup. No single facility-specific major capex.

Maintenance capex to sustain scaling; implies capital-intensive oral solids business model.

35 approved ANDAs planned for launch in 18-20 months. Q1 saw 7 launches contribute negligibly to revenue, raising risk that pipeline visibility isn't converting to timely commercial ramp.

H1 emerging market EBITDA margin fell 20%→14% QoQ. Full-year guidance 18-20% requires significant H2 recovery; dependent on new product registrations and price realization.

Q1 PAT growth 43.8% YoY; FY27 guidance 50-60%. Shortfall of ~600-1600 bps suggests Q2-Q4 must accelerate sharply or full-year target at risk. Management claims on-track but hedged.

Sequential gross margin slight decline; management attributes to product mix (regulated vs emerging) and seasonality. Risk: if mix stays unfavorable, EBITDA target at risk despite top-line growth.

US considering tariffs on generic pharma imports effective 2028. While Senores has US facility (Apnar) and US manufacturing, exposure depends on tariff scope and India-US trade deal specifics.